Ling Yi

455 total citations
17 papers, 331 citations indexed

About

Ling Yi is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ling Yi has authored 17 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Immunology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ling Yi's work include Cancer Immunotherapy and Biomarkers (10 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (4 papers). Ling Yi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (4 papers). Ling Yi collaborates with scholars based in China, Netherlands and Australia. Ling Yi's co-authors include N. Ray Dunn, Davor Solter, Serene C. Chng, Chin Yan Lim, Gijs Afink, Daniel M. Messerschmidt, Marie van Dijk, Barbara B. Knowles, Bruno Reversade and Sheena L. M. Ong and has published in prestigious journals such as Science, SHILAP Revista de lepidopterología and Human Molecular Genetics.

In The Last Decade

Ling Yi

17 papers receiving 329 citations

Peers

Ling Yi

PHARM

SURGE

ONCOL

Xiulong Niu China

Geriolda Topi Sweden

Canqiao Luo China

Zhongping Cheng China

Ryu Iwasaki Japan

Toshiaki Narasaka Japan

Jayakumar Manoharan Germany

Shani Austin‐Williams United Kingdom

Sarika Gupta United States

Xiaoming Shi China

Xiulong Niu China

Ling Yi

23 ×0.2

PHARM

45 ×0.5

SURGE

110 ×1.4

71 ×1.0

ONCOL

105 ×1.7

Citations per year, relative to Ling Yi Ling Yi (= 1×) peers Xiulong Niu

Countries citing papers authored by Ling Yi

Since Specialization

Citations

This map shows the geographic impact of Ling Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Yi more than expected).

Fields of papers citing papers by Ling Yi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Yi. The network helps show where Ling Yi may publish in the future.

Co-authorship network of co-authors of Ling Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Yi. A scholar is included among the top collaborators of Ling Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Yi. Ling Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Zhang, Huan, et al.. (2025). Epigenetic regulators combined with tumour immunotherapy: current status and perspectives. Clinical Epigenetics. 17(1). 51–51. 7 indexed citations

Yi, Ling, Ziwei Xu, Tianyu Ma, et al.. (2024). T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC. Cancer Immunology Immunotherapy. 73(6). 99–99. 5 indexed citations

Yi, Ling, et al.. (2023). Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. Discover Oncology. 14(1). 35–35. 5 indexed citations

Gao, Xiang, Ling Yi, Chang Jiang, et al.. (2023). PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer. Frontiers in Immunology. 14. 1142428–1142428. 17 indexed citations

Li, Shuping, Ling Yi, Jinguo Zhang, et al.. (2022). Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. Frontiers in Cardiovascular Medicine. 9. 971414–971414. 3 indexed citations

Ma, Tianyu, Tao Wen, Cheng Xu, et al.. (2022). Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer. Lung Cancer. 172. 43–52. 6 indexed citations

Yi, Ling, Xin Jin, Jinghui Wang, et al.. (2022). CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer. Frontiers in Immunology. 13. 771809–771809. 6 indexed citations

Chang, Jiang, Ling Yi, Xiang Gao, Hongtao Zhang, & Shucai Zhang. (2022). [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].. SHILAP Revista de lepidopterología. 25(1). 46–53. 1 indexed citations

Ma, Li, Ling Yi, Cheng Xu, et al.. (2022). CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer. Clinical & Experimental Immunology. 208(2). 220–232. 12 indexed citations

10.

Liu, Zhongqiang, Lina Qiao, Deyuan Li, Li Yu, & Ling Yi. (2021). Chronic cavitary pulmonary aspergillosis in an infant. The Lancet Infectious Diseases. 21(12). 1757–1757. 1 indexed citations

11.

Wang, Helin, Jian Yu, Xiaona Mao, et al.. (2021). Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer. Neoplasma. 68(4). 823–831. 4 indexed citations

12.

Zhao, Bing, Yu Pang, Ling Yi, et al.. (2020). Generation of mycobacterial lipoarabinomannan-specific monoclonal antibodies and their ability to identify mycobacterium isolates. Journal of Microbiology Immunology and Infection. 54(3). 437–446. 16 indexed citations

13.

Zhang, Qi, Jingying Nong, Jinghui Wang, et al.. (2019). Isolation of circulating tumor cells and detection of EGFR mutations in patients with non‑small‑cell lung cancer. Oncology Letters. 17(4). 3799–3807. 19 indexed citations

14.

Wang, Helin, Bin Yang, Jinghui Wang, et al.. (2019). CD137 ligand feedback upregulates PD‐L1 expression on lung cancer via T cell production of IFN‐γ. Thoracic Cancer. 10(12). 2225–2235. 12 indexed citations

15.

Nong, Jingying, Jinghui Wang, Xin Gao, et al.. (2019). Circulating CD137⁺CD8⁺ T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients. Scandinavian Journal of Immunology. 89(6). e12765–e12765. 6 indexed citations

16.

Ho, Lena, Marie van Dijk, Daniel M. Messerschmidt, et al.. (2017). ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science. 357(6352). 707–713. 168 indexed citations

17.

Yi, Ling, Anthony Donsante, Marina Kennerson, et al.. (2011). Altered intracellular localization and valosin-containing protein (p97 VCP) interaction underlie ATP7A-related distal motor neuropathy. Human Molecular Genetics. 21(8). 1794–1807. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact